Karmi

Karmi from Truist Securities inquired about the improvement in ARC-20 casdatifan monotherapy's ORR from the 30s to the mid-40s, asking if it was due to deepening responses and at what time points these responses typically occurred. Karmi also asked about the clinical and R&D impact of the STAR-121 futility analysis.

Answer

CEO Terry Rosen confirmed the ORR improvement was entirely due to deepening responses, which can occur at various time points, even beyond a year, attributing this to the drug's benign safety profile. CFO Bob Goeltz added that the operational impact of discontinuing STAR-121 would be minimal as the study is largely enrolled, and R&D expenses are expected to decrease as the trial concludes.